Congratulations to Keith Hoffman on joining Athos Therapeutics as its Chief Business Officer!

This is a perfect example of our innovation ecosystem at work. Even before BioscienceLA formed, our team was excited to see Keith move from San Diego to Los Angeles to grow The Lundquist Institute and the life sciences community here. The Lundquist Institute and BioLabs at The Lundquist Institute were instrumental in keeping Athos here in LA, rather than moving to another region. And now Keith is taking on an important new role to expand Athos into the clinical stage.

The BioscienceLA team looks forward to ongoing collaborations with Keith, Athos, The Lunquist Institute, and BioLabs.

— On Monday, November 2, 2020, Athos Therapeutics Inc., a late pre-clinical stage biotechnology company pioneering the development of first-in-class precision therapeutics for patients with autoimmune diseases and cancer, announced the appointment of Keith Bronson Hoffman, Ph.D. as their Chief Business Officer. In this role, Dr. Hoffman will oversee business development, funding, and partnerships, and will report to Dimitrios Iliopoulos, PhD, MBA, Chief Executive Officer.

You can read the full announcement here.